Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system.
Peripheral neuropathies occur in 5% of patients with Non-Hodgkin Lymphoma and represent the effects of therapy, direct compression or nerve infiltration by tumor, or paraneoplastic effects. Multifocal motor neuropathy with conduction block (MMNCB) is a rare demyelinating disorder of unknown etiology characterized by progressive, distal, asymmetric weakness mostly of the upper limbs with minimal or no sensory loss. We report a patient, who developed MMNCB at the time of isolated CNS relapse from a diffuse large B-cell lymphoma. Marked neurological improvement was achieved using intravenous immunoglobulin treatment. To our knowledge, MMNCB has thus far not been described as part of the spectrum of lymphoma-related peripheral neuropathies.
Department of Neurology, Brain Tumor Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Britta V
BV
Stern
Joachim M
JM
Baehring
Kleopas A
KA
Kleopa
Fred H
FH
Hochberg
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003711:Demyelinating Diseases / Q000150:complications / Q000503:physiopathology; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000150:complications* / Q000503:physiopathology; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009423:Nervous System Neoplasms / Q000150:complications* / Q000188:drug therapy; D009431:Neural Conduction; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000503:physiopathology; D012535:Scalp / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology; D013852:Thiotepa / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D014750:Vincristine; D003520:Cyclophosphamide; D013852:Thiotepa; D008727:Methotrexate